Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Search Results

Product Details for NDA 209501

Expand all

LYRICA CR (PREGABALIN)
82.5MG
Marketing Status: Prescription

Active Ingredient: PREGABALIN
Proprietary Name: LYRICA CR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 82.5MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N209501
Product Number: 001
Approval Date: Oct 11, 2017
Applicant Holder Full Name: UPJOHN US 2 LLC
Marketing Status:  Prescription
Patent and Exclusivity Information

LYRICA CR (PREGABALIN)
165MG
Marketing Status: Prescription

Active Ingredient: PREGABALIN
Proprietary Name: LYRICA CR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 165MG
Reference Listed Drug: Yes
Reference Standard: No
TE Code: AB
Application Number: N209501
Product Number: 002
Approval Date: Oct 11, 2017
Applicant Holder Full Name: UPJOHN US 2 LLC
Marketing Status:  Prescription
Patent and Exclusivity Information

LYRICA CR (PREGABALIN)
330MG
Marketing Status: Prescription

Active Ingredient: PREGABALIN
Proprietary Name: LYRICA CR
Dosage Form; Route of Administration: TABLET, EXTENDED RELEASE; ORAL
Strength: 330MG
Reference Listed Drug: Yes
Reference Standard: Yes
TE Code: AB
Application Number: N209501
Product Number: 003
Approval Date: Oct 11, 2017
Applicant Holder Full Name: UPJOHN US 2 LLC
Marketing Status:  Prescription
Patent and Exclusivity Information